Figure 3From: An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophreniaPercentage of subjects with improved, the same, or worsened clinical status at the 6-month end point, by Clinical Global Impressions of Severity ratings. Intent-to-treat population, last observation carried forwardBack to article page